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Abstract
Background: The once-weekly (QW) formulation of the glucagon-like peptide-1 receptor agonist exenatide has
been demonstrated to improve A1C, fasting plasma glucose (FPG), body weight, serum lipid profiles, and blood
pressure in patients with type 2 diabetes through 52 weeks of treatment. In this report, we describe the 2-year
results of the open-label, open-ended extension to the DURATION-1 trial of exenatide QW for type 2 diabetes.
Methods: A 2-stage protocol was used: patients received either exenatide QW (2 mg) or exenatide twice daily for
30 weeks (5 μg for the first 4 weeks and 10 μg thereafter), followed by 1.5 years of treatment with exenatide QW
(2 mg), for a total of 2 years (104 weeks) of exenatide treatment. Of the 295 (intent-to-treat [ITT]) patients who
entered the trial, 73% (n = 216) completed 2 years of treatment (completer population). Baseline characteristics
(mean ± SE) for these patients were: A1C, 8.2 ± 0.1%; FPG, 168.4 ± 43.0 mg/dL; body weight, 101.1 ± 18.7 kg; and
diabetes duration, 7 ± 5 years.
Results: In the completer population, significant improvements (LS mean ± SE [95% CI]) were maintained after
2 years of treatment in A1C (-1.71 ± 0.08% [-1.86 to -1.55%]), FPG (-40.1 ± 2.9 mg/dL [-45.7 to -34.5 mg/dL]), and
body weight (-2.61 ± 0.52 kg [-3.64 to -1.58 kg]) compared with baseline. The percentages of patients who
achieved an A1C of <7.0% and ≤6.5% at 2 years were 60% and 39%, respectively. A significant reduction in systolic
blood pressure (SBP; -3.0 ± 1.0 mmHg [-4.9 to -1.1 mmHg]) was maintained through 2 years of treatment. Serum
lipid profiles were also significantly improved, including triglycerides (geometric LS mean change from baseline,
-15 ± 2.7% [-21% to -10%]), total cholesterol (-8.6 ± 2.8 mg/dL [-14.0 to -3.1 mg/dL]), and low-density lipoproteins
(-4.5 ± 2.2 mg/dL [-8.9 to -0.01 mg/dL]). Changes in A1C, body weight, FPG, SBP, and lipids in the ITT population
were similar to those seen in the completer population. Nausea (predominantly mild in intensity) was the most
common adverse event, although the frequency and intensity of nausea decreased over time. No severe
hypoglycemia was observed.
Conclusions: Exenatide QW was well tolerated during the 2-year treatment period. This study demonstrated
sustained glucose control and weight loss throughout 2 years of treatment with exenatide QW.
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Type 2 diabetes is characterized by progressive insulin
resistance and pancreatic beta-cell dysfunction result-
ing in key defects in insulin secretion and function [1].
Ultimately, this leads to difficulties in controlling
hyperglycemia, which has been associated with micro-
vascular and macrovascular complications [2,3].
Because lowering of A1C has been shown to reduce
the risk of long-term microvascular - and possibly
macrovascular - complications [3-7], a target A1C level
of <7% has been recommended by the American Dia-
betes Association (ADA) [8] for patients with diabetes;
the American Association of Clinical Endocrinologists
and the American College of Endocrinology (AACE/
ACE) [9] have recommended a more stringent A1C
target of ≤6.5%. Thus, the overall goal for the treat-
ment of type 2 diabetes is to reduce A1C to as near
normal levels as possible, with considerations for the
risk of hypoglycemia and the risk of comorbidites that
are common in type 2 diabetes, including obesity, dysli-
pidemia, and hypertension.
Treatment of type 2 diabetes often begins with life-
style modifications, but as the disease progresses, most
patients require pharmacotherapy. However, many
patients with type 2 diabetes do not maintain the
recommended glycemic targets over time with tradi-
tional therapies and must transition to combination
therapy and/or increasing doses of insulin as their glyce-
mic control deteriorates [5,6,10,11]. Furthermore, the
use of many antihyperglycemic agents can be accompa-
nied by increased hypoglycemia, weight gain, and a per-
sistence of elevated postprandial glucose excursions [3].
To address the need for more comprehensive treatment
of type 2 diabetes, recent algorithms developed by the
AACE and ADA/European Association for the Study of
Diabetes have recommended the use of glucagon-like
peptide-1 (GLP-1) receptor agonists (monotherapy or
combination therapy) on the basis of their effective gly-
cemic control, weight loss effects, low rates of hypogly-
cemia, and overall safety profiles, and particularly for
use in patients for whom hypoglycemia is especially
undesirable or promotion of weight loss is a major con-
sideration [2,9,11].
Exenatide is a potent GLP-1 receptor agonist with
multiple glucoregulatory effects for the treatment of
type 2 diabetes [12-18]. Treatment with exenatide twice
daily (BID) enhances glucose-dependent insulin secre-
tion, reduces inappropriate elevations in glucagon secre-
tion, slows gastric emptying, and reduces body weight in
a substantial proportion of treated patients [13-19].
Furthermore, the clinical effects of exenatide are sus-
tained over time, as shown in long-term studies of exe-
natide BID [19,20].
The sustained-release formulation of exenatide, exena-
tide once-weekly (QW), allows for continuous drug
release over time, resulting in sustained therapeutic
levels of exenatide - and thus, 24-hour glycemic control
- with a single weekly injection [21,22]. Providing con-
tinuous GLP-1 receptor agonism has emerged as an
increasingly important opportunity in treating type 2
diabetes, as evidence indicates that controlling both fast-
ing and postprandial hyperglycemia is essential to pro-
viding comprehensive glycemic control [23,24].
The DURATION-1 trial was designed to compare the
safety and efficacy of exenatide BID with exenatide QW
in patients with type 2 diabetes. This 2-stage protocol
consisted of a randomized, open-label comparison of
exenatide QW and exenatide BID for 30 weeks, followed
by an open-ended assessment period in which all
patients received exenatide QW. The results from the
30- and 52-week assessment periods have previously
been reported [25,26]. The objective of this report is to
describe the safety and efficacy of 2 years of exenatide
QW treatment in patients with type 2 diabetes.
Methods
Randomization and interventions
Patients were randomized to one of two open-label treat-
ment groups: 1) weekly subcutaneous (SC) injections of
2 mg exenatide QW or 2) SC injections of exenatide 5
μg BID for the first 4 weeks followed by a dose increase
to 10 μg BID for the remainder of the 30-week assess-
ment period. The inclusion and exclusion criteria have
previously been reported [25]. At 30 weeks, participants
entered an open-ended treatment period in which all
patients received exenatide QW. Patients who were ori-
ginally randomized to exenatide BID were switched to
exenatide QW, and those originally randomized to exena-
tide QW continued their treatment regimens. Patients
who were switched to exenatide QW at week 30 and
who were concomitantly using a sulfonylurea (SFU) were
required to reduce the SFU dose to the minimum recom-
mended dose until week 40. Subsequently, the SFU dose
was titrated up based on daily glucose measurements to a
target fasting plasma glucose (FPG) of ≤110 mg/dL.
A common clinical protocol was approved for each
study site by the appropriate Institutional Review Board.
Patients provided written informed consent prior to par-
ticipation. The study was conducted in accordance with
the principles described in the Declaration of Helsinki,
including all amendments through the South Africa
revision of 1996 [27].
Outcomes
The objectives of this study were to examine the effects
of exenatide QW on glycemic control, body weight,
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ment. Efficacy, safety, and tolerability were assessed in
all patients, including intent-to-treat (ITT) and comple-
ter populations. Plasma analytes and A1C were quanti-
tated by Quintiles Laboratories (Smyrna, GA) using
standard methods [25].
Statistical analysis
All randomized patients who received at least one injec-
tion of exenatide in the 30-week phase of this study were
defined as the ITT population. The 2-year (104-week)
completer population consisted of patients from the ITT
population who completed the study procedures through
week 100 in compliance with the protocol and who
received at least 96 weeks of treatment. At week 52,
there were no significant differences in change from base-
line A1C or the percentage of patients who achieved tar-
get A1C between the group initially randomized to
exenatide QW and the group initially randomized to exe-
natide BID (who switched to exenatide QW at week 30)
[26]. Thus, in this 2-year assessment, the completer
population consisted of all patients regardless of initial
randomization. Descriptive statistics on demographics
and analyses of primary glycemic endpoints, body weight,
blood pressure, and fasting lipid concentrations are pro-
vided for both the completer and ITT populations. For
ITT analyses, the last observation carried forward
(LOCF) method was applied to include data collected
from the early withdrawals. The analyses of A1C were
based on a general linear model (ANOVA) including ori-
ginal treatment assignment, baseline A1C strata, and con-
comitant SFU use at screening as factors. Baseline FPG,
body weight, and blood pressure were added in the
model (ANCOVA) for each respective parameter. Efficacy
endpoint results are expressed as least square (LS)
means. Statistical analysis was performed using SAS (8.2;
SAS Institute, Inc., North Carolina).
Treatment-emergent adverse events (TEAEs) were
defined as events that occurred during or after the first
injection of randomized treatment. Hypoglycemic epi-
sodes were classified as major (i.e., severe) if 1) the
event resulted in loss of consciousness, seizure, coma, or
other change in mental status consistent with neurogly-
copenia (as judged by the investigator or physician), in
which symptoms resolved after administration of intra-
muscular glucagon or intravenous glucose, or 2) the
event required third-party assistance because of severe
impairment in consciousness or behavior and was
accompanied by a blood glucose concentration of <54
mg/dL (3.0 mmol/L). Minor hypoglycemia was defined
as a report of symptoms consistent with hypoglycemia
and a glucose value of <54 mg/dL prior to treatment of
the episode. Safety analyses are provided for the ITT
population.
Results
Patient disposition and baseline characteristics
Demographic characteristics of the completer population
(n = 216) are described in Figure 1. Of the 295 patients
included in the ITT population, 73% completed 2 years
of treatment (Figure 1). The most common reason for
study withdrawal was withdrawal of consent. The demo-
graphic characteristics of the ITT population (sex, 53%
male; mean age, 55 y; Caucasian, 78%; Black, 10%; His-
panic, 12%; Asian, <1%; mean weight, 102 kg; body mass
index, 35 kg/m
2; A1C, 8.3; FPG, 169 mg/dL; duration of
diabetes, 7 y) were nearly identical to the 2-year comple-
ter population.
Effects on glycemic control and body weight
The results reported here for the completer population
and ITT population consist of all patients regardless of
initial randomization. Overall, patients in the 2-year
completer population maintained improvements in A1C
(Figure 2A), with LS mean ± SE (95% CI) change from
baseline A1C of -1.7 ± 0.08% (-1.86 to -1.55%). The
mean change from baseline A1C in the ITT population
was -1.5 ± 0.07%. At the end of the 2-year assessment
period, 60% of patients achieved A1C of <7.0%, 39%
achieved A1C of ≤6.5%, and 17% achieved normoglyce-
mia (i.e., ≤6.0%) (Figure 2B). The percentage of patients
in the ITT population who achieved these glycemic
goals were similar to those in the completer population
and are shown Figure 2B. Overall, 89% of patients in the
completer population achieved a reduction in A1C at
year 2 (Figure 3B). In patients who received 2 years of
treatment, FPG decreased by 40.1 ± 2.9 mg/dL (-45.7 to
-34.5 mg/dL) (Figure 2C).
Body weight reduction was generally maintained dur-
ing the study; at the end of the 2-year assessment per-
iod, body weight (mean ± SE [95% CI]) was reduced by
2.6 ± 0.5 kg (-3.64 to -1.58 kg) in the completer popula-
tion and 2.4 ± 0.4 kg (-3.19 to -1.53 kg) in the ITT
population (Figure 3A). The distribution of the change
in A1C with respect to changes in body weight is shown
in Figure 3B for the completer population. At 2 years of
treatment, 66% of patients experienced weight loss and
61% achieved reductions in both A1C and body weight.
Effects on blood pressure and fasting lipids
Significant improvements in systolic blood pressure (SBP)
were observed in patients treated with exenatide QW
(Figure 3C): the mean change ± SE (95% CI) from base-
line was -3.0 ± 1.0 mmHg (-4.9 to -1.1 mmHg) in the
completer population and -2.1 ± 1.0 mmHg (-3.8 to -0.5
mmHg) in the ITT population. Improvement in diastolic
blood pressure (data not shown) was also significant in
the completer population (-1.5 ± 1.0 mmHg [-2.8 to -0.2
mmHg]), but not in the ITT population (-0.8 ± 0.6
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Page 3 of 9Figure 1 Enrollment, patient disposition, and baseline characteristics. Of the 303 patients originally randomized to the study, 295
comprised the ITT population and 258 entered the subsequent 74-week assessment period (ITT population). Forty-two patients withdrew during
the 74-week open-ended assessment period, resulting in a completer population of n = 216. The disposition and demographic characteristics of
the 30-week and 52-week populations have been published previously [25,26].
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change [95% CI]) in serum lipid profiles were demon-
strated after 2 years of treatment (completer population),
with clinically significant reductions from baseline in total
cholesterol (-8.6 ± 2.8 mg/dL [-14.0 to -3.1 mg/dL]), low-
density lipoproteins (LDL; -4.5 ± 2.2 mg/dL [-8.9 to -0.01
mg/dL]), and triglycerides (geometric LS mean percent
change ± SE -15 ± 2.7% [-21% to -10%]; Figure 3D).
Similarly, changes in the ITT population were -8.2 ± 2.3
mg/dL (-12.7 to -3.7 mg/dL) for total cholesterol, -3.9 ±
1.8 mg/dL (-7.5 to -0.3 mg/dL) for LDL, and -12 ± 2.7%
(-21% to -10%) for triglycerides.
Safety and tolerability
Frequent (≥5%) TEAEs that occurred for the first time or
worsened after receiving exenatide QW from weeks 0 to
30 and weeks 30 to 104 (ITT population) are described
in Table 1. The adverse event (AE) profile for exenatide
BID treatment from weeks 0 to 30 was previously
reported [25]. Overall, the types of events reported with
exenatide were similar for the controlled (weeks 0-30)
and uncontrolled (weeks 30-104) portions of the trial,
with no new tolerability or safety issues identified. Nausea
was the most common AE throughout the trial and was
predominantly mild in intensity; no severe nausea was
reported. The proportion of patients who experienced
nausea decreased during the second phase (weeks 30-
104) of the trial: the incidence of nausea during the initial
30 weeks of treatment was 27% in the exenatide QW
group and 35% in exenatide BID group, both of which
decreased to 12%, regardless of initial treatment, from
week 30 to week 104. The incidence of injection site
pruritis and injection site erythema also declined from
week 30 (18% and 7%, respectively) to week 104 (4% for
both), and no injection-site-related AEs led to withdrawal
during the uncontrolled period. There were no episodes
of major hypoglycemia. Of the 17 patients who experi-
enced a minor hypoglycemic event between weeks 30
and 104, 16 were using a concomitant SFU. From week
30 to week 104, only 4 patients withdrew because of an
AE: nausea, cholestatic hepatitis, positive antibody test,
diabetes mellitus, and breast cancer. The incidence of ser-
ious AEs was generally low (11% at week 104) and there
was no consistent pattern of reported events. Addition-
ally, no cases of pancreatitis were reported.
Discussion
Guidelines for the treatment of type 2 diabetes are cur-
rently focused on the use of agents that provide effective
lowering of A1C, have beneficial effects on extraglycemic
factors associated with long-term complications, and have
favorable safety and tolerability profiles [9,28]. Recently,
GLP-1 receptor agonists have been recommended as a
treatment option for patients in whom hypoglycemia or
weight gain are major concerns [9,11]. In particular,
weight loss in type 2 diabetes is associated with improved
insulin action and enhanced glycemic control [29], and it
may favorably affect other comorbidites associated with
diabetes such as hypertension and dyslipidemia [30].
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Figure 2 Improvements in glycemic control over 104 weeks in
the completer population (N = 216) and intent-to-treat
population (N = 295). A) LS mean ± SE changes in A1C over 104
weeks. Baseline (BL) was 8.2% in the 2-year completer population
and 8.3% in the ITT population. B) Proportion of patients who
achieved A1C targets of <7.0%, ≤6.5%, and ≤6.0%. C) LS mean ± SE
changes in fasting plasma glucose over 104 weeks. Baseline was
168 mg/dL in the 2-year completer population and 169 mg/dL in
the ITT population.
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Page 5 of 9The improvements in glycemic control that were pre-
viously reported with 52 weeks of exenatide QW treat-
ment [26] were sustained in the present study in patients
continuing exenatide QW treatment for 2 years, regardless
of the initial 30-week randomization of treatment (i.e.,
QW or BID). After 2 years of treatment, reductions in
A1C remained durable in all patients (LS mean A1C
change, -1.7%). In addition to improvements in glycemic
control, improvements were seen in several cardiovascular
risk factors including body w e i g h t ,b l o o dp r e s s u r e ,a n d
fasting lipids. Further studies are warranted to determine
whether these improvements are associated with enhanced
outcomes in patients with type 2 diabetes.
Exenatide once weekly vs. exenatide twice daily
Previously reported results from this trial demonstrated
that improvements in glycemic control achieved with
exenatide QW were greater than those achieved with exe-
natide BID, with similar or greater improvements in other
outcomes including body weight, blood pressure, and
serum lipid profiles [25,26]. After 30 weeks of treatment,
patients who received exenatide QW had a greater mean
A1C reduction (-1.9% vs. -1.5%) than did patients who
received exenatide BID, and more exenatide QW-treated
patients achieved target A1C levels of <7.0% (77% vs. 61%)
[25]. Of note, patients who switched from exenatide BID
to exenatide QW at week 30 exhibited further improve-
ments in glycemic control such that at week 52, all
patients, regardless of initial treatment, exhibited similar
mean A1C reductions (-2.0%) [26]. In the present analysis,
the observed mean A1C reduction of 1.7% after 2 years of
treatment suggests that glycemic control is maintained
with exenatide QW, a finding that was also observed after
2 years of treatment with exenatide BID [20].
Figure 3 Improvements in body weight, blood pressure, and serum lipids. A) LS mean ± SE changes in body weight at 2 years for the ITT
(N = 295) and completer populations (N = 216). B) Reductions in both body weight and A1C in the completer population after 104 weeks. C)
LS mean change from baseline ± SE in systolic blood pressure (SBP) after 104 weeks of treatment, further analyzed by normal or abnormal
baseline SBP, in the completer population (N = 216; Normal baseline, n = 113; Abnormal baseline, n = 103) and ITT population (All, N = 295;
Normal baseline, n = 158; Abnormal baseline, n = 137). D) Changes in serum lipids were seen at week 104 (completer and IIT populations): data
are presented as LS mean ± SE for all lipids except for triglycerides (geometric LS mean percent change ± SE from baseline).
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peptidase-4 (DDP-4) inhibitors
Other GLP-1-related therapies currently available for the
treatment of type 2 diabetes are the once-daily GLP-1
receptor agonist, liraglutide, and the once-daily DPP-4
inhibitors sitagliptin and saxagliptin [31-33]. The GLP-1
receptor agonists (exenatide BID or QW and liraglutide)
have been shown to be more efficacious at providing glyce-
mic control and promoting weight loss than the DPP-4
inhibitors, although with more gastrointestinal side effects
than with DPP-4 inhibitors [31,34,35]. A comparison study
between exenatide BID and liraglutide showed that both
therapies had significant effects on A1C, as determined by
a noninferiority comparison [31]; however, reductions were
significantly greater with liraglutide (mean A1C change,
-1.1%) than with exenatide BID (-0.8%). Weight loss was
similar between exenatide BID and liraglutide (approxi-
mately 3 kg). At this time, the results of a comparison
study of exenatide QW and liraglutide are not yet available
(ClinicalTrials.gov Identifier NCT01029886).
Safety and tolerability
Treatment with exenatide QW was safe and well tolerated
during the 2-year assessment period, with a retention rate
of 73%. Adverse events (AEs) were generally mild to mod-
erate. Few patients who received exenatide QW withdrew
due to an AE (1.4% in the uncontrolled period) and there
were no withdrawals from the study due to serious AEs.
Mild nausea was common, but the frequency and severity
of nausea decreased or abated over time. To date, no
safety signals specific to exenatide QW have been identi-
fied in clinical trials.
Study limitations
There were several potential limitations of this study.
The absence of a comparator arm during the 1.5-year
uncontrolled period limits the conclusions that can be
drawn from the results, and the open-label trial design
inherently creates the potential for bias and can affect
patient expectations. The trial design also complicates
interpretation of the modest increases in A1C, FPG, and
body weight seen from week 52 to week 104. Further-
more, the population was heterogeneous for background
therapy with other antidiabetic drugs; however, the ear-
lier results at 30 and 52 weeks in this study suggest that
the data are consistent across populations, regardless of
background therapy.
Results from both the ITT and completer populations
were included in this study, and both populations pre-
sent certain limitations to the interpretation of the
results. For the ITT analysis, using a LOCF method is a
conservative approach that accounts for early study
withdrawal and provides a prediction of treatment effect
for any subject who ever received treatment. The com-
pleter analysis mitigates the potentially large variations
in treatment exposure by representing the actual efficacy
for the full term of drug exposure. The results of the
ITT analysis should, thus, be weighed against the results
of the completer analysis, as efficacy data collected early
in the trial (e.g., from subjects who withdrew early) may
not be representative of the true treatment effect, which
is established with increased duration of treatment
exposure. However, subject retention is often a chal-
lenge in long-term trials and the results of the comple-
ter analysis may be affected by the composition of the
completer population, which often includes a high pro-
portion of subjects who experienced favorable outcomes
with treatment and underrepresents subjects who had
issues with tolerability or lack of efficacy.
Conclusions
The present analysis demonstrated durable efficacy with
long-term exenatide QW therapy and showed that com-
mon AEs, especially nausea, subsided with time. The
continuous release of exenatide in the once-weekly for-
mulation produced continuous GLP-1 receptor activa-
tion leading to sustained control of both fasting and
postprandial hyperglycemia, which resulted in enhanced
Table 1 Frequent (≥5%) Treatment-emergent Adverse
Events with Exenatide Once Weekly During Weeks 0 to
30 and Weeks 30 to 104
Adverse Event Weeks 0 to 30
(n = 148*)
(% of patients)
Weeks 30 to 104
(n = 258
†)
(% of patients)
Nausea 27 12
Vomiting 11 9
Diarrhea 15 12
Constipation 11 5
Dyspepsia 7 3
Gastroesophageal reflux disease 7 4
Injection site pruritus 18 4
Injection site erythema 7 4
Urinary tract infection 10 9
Gastroenteritis viral 9 7
Nasopharyngitis 7 16
Upper respiratory tract infection 8 24
Sinusitis 5 12
Influenza 1 5
Headache 6 5
Fatigue 6 4
Back pain 5 7
Arthralgia 5 6
Pain in extremity 1 6
*Patients randomized to exenatide QW.
†Patients who continued exenatide QW or switched from exenatide BID to
exenatide QW.
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the once-weekly injection of exenatide offers an attrac-
tive alternative to once- and twice-daily injections, and
could improve treatment adherence in the clinical set-
ting [36]. This combination of effects suggests that the
use of exenatide QW may be a viable, long-term option
for the treatment of patients with type 2 diabetes.
Abbreviations
AE: adverse event; BID: twice daily; BL: baseline; FPG: fasting plasma glucose;
GLP-1: glucagon-like peptide-1; ITT: intent-to-treat; LOCF: last observation
carried forward; LS: least squares; QW: once-weekly; SBP: systolic blood
pressure; SC: subcutaneous; SD: standard deviation; SE: standard error; SFU:
sulfonylurea.
Acknowledgements
The studies in this analysis were sponsored by Amylin Pharmaceuticals, Inc,
San Diego, California, and Eli Lilly and Company, Indianapolis, Indiana. The
authors thank the exenatide DURATION-1 (Diabetes Therapy Utilization:
Researching Changes in A1C, Weight and Other Factors Through
Intervention with Exenatide ONce Weekly) clinical team for their assistance
in the conduct, reporting, and quality control of the studies; the DURATION-
1 study site investigators (Sherwyn Schwartz, Sam Miller, Richard Weinstein,
Bethany Klopfenstein, Andrew Ahmann, Julio Rosenstock, John Pullman, Fred
Whitehouse, G.M. Gollapudi, Douglas Schumacher, Mervyn Weerasinghe,
Peter Weissman, Lyle Myers, Eric Klein, Thomas Littejohn, Thomas Moretto,
Jon Shapiro, Daniel Lorber, Athena Philis-Tsimikas, David Kayne, Richard
Bergenstal, Elizabeth Stevens, Danny Sugimoto, Bruce Berwald, Diane Krieger,
Dean Kereiakes, Gary Lewis, Robert Henry, Mark Comianos, Munni
Selagamsetty, Ronald Mayfield, John Buse and Daniel Drucker) and their
staffs for conducting the study; the study patients for their participation; and
Alkermes, Inc. for the development of and for manufacturing the long-acting
release formulation of exenatide. Portions of these data were previously
presented at the ADA 69
th Scientific Sessions, New Orleans, Louisiana 2009.
Author details
1Amylin Pharmaceuticals, Inc., 9360 Towne Centre Drive, San Diego, CA
92121, USA.
2Eli Lilly and Company, Lilly Corporate Center: DC 6038,
Indianapolis, IN 46285, USA.
Authors’ contributions
KT, JH, and RP participated in the design of the analysis. JH and RP
performed the statistical analysis. All authors were involved in the
interpretation of the analysis. All authors were involved in drafting the
manuscript or revising it critically for important intellectual content. All
authors approved the final manuscript.
Competing interests
This study was funded by Amylin Pharmaceuticals, Inc. and Eli Lilly and
Company. Dr. Gurney, Ms. Han, Dr. Pencek, and Dr. Walsh are employees of
Amylin Pharmaceuticals, Inc. Dr. Taylor was previously an employee of
Amylin Pharmaceuticals, Inc. Dr. Trautmann is an employee of Eli Lilly and
Company. Amylin Pharmaceuticals, Inc. has a global agreement with Eli Lilly
and Company to collaborate on the development and commercialization of
exenatide. All authors own company stock and have stock options.
Received: 12 October 2010 Accepted: 29 April 2011
Published: 29 April 2011
References
1. Kahn SE: The relative contributions of insulin resistance and beta-cell
dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia
2003, 46(1):3-19.
2. Kendall DM, Cuddihy RM, Bergenstal RM: Clinical application of incretin-
based therapy: therapeutic potential, patient selection and clinical use.
Am J Med 2009, 122(6 Suppl):S37-S50.
3. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG:
Exenatide versus insulin glargine in patients with suboptimally
controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005,
143(8):559-569.
4. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC: UKPDS 26:
Sulphonylurea failure in non-insulin-dependent diabetic patients over
six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med
1998, 15(4):297-303.
5. United Kingdom Prospective Diabetes Study (UKPDS): 13: Relative efficacy
of randomly allocated diet, sulphonylurea, insulin, or metformin in
patients with newly diagnosed non-insulin dependent diabetes followed
for three years. BMJ 1995, 310(6972):83-88.
6. UK Prospective Diabetes Study (UKPDS) Group (UPDSG): Intensive blood-
glucose control with sulphonylureas or insulin compared with
conventional treatment and risk of complications in patients with type 2
diabetes (UKPDS 33). Lancet 1998, 352(9131):837-853.
7. Greenfield S, Billimek J, Pellegrini F, Franciosi M, De Berardis G, Nicolucci A,
Kaplan SH: Comorbidity affects the relationship between glycemic
control and cardiovascular outcomes in diabetes: a cohort study. Ann
Intern Med 2009, 151(12):854-860.
8. American Diabetes Association: Standards of medical care in diabetes.
Diabetes Care 2004, 27(Suppl 1):S15-S35.
9. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G,
Handelsman Y, Horton ES, Lebovitz H, Levy P, et al: Statement by an
American Association of Clinical Endocrinologists/American College of
Endocrinology consensus panel on type 2 diabetes mellitus: an
algorithm for glycemic control. Endocr Pract 2009, 15(6):540-559.
10. Turner RC, Cull CA, Frighi V, Holman RR: Glycemic control with diet,
sulfonylurea, metformin, or insulin in patients with type 2 diabetes
mellitus: progressive requirement for multiple therapies (UKPDS 49). UK
Prospective Diabetes Study (UKPDS) Group. JAMA 1999,
281(21):2005-2012.
11. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R,
Zinman B: Medical management of hyperglycemia in type 2 diabetes: a
consensus algorithm for the initiation and adjustment of therapy: a
consensus statement of the American Diabetes Association and the
European Association for the Study of Diabetes. Diabetes Care 2009,
32(1):193-203.
12. Göke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Göke B: Exendin-
4 is a high potency agonist and truncated exendin-(9-39)-amide an
antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of
insulin-secreting β-cells. J Biol Chem 1993, 268(26):19650-19655.
13. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD, Exenatide-113
Clinical Study Group: Effects of exenatide (exendin-4) on glycemic control
over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
Diabetes Care 2004, 27(11):2628-2635.
14. Nielsen LL, Young AA, Parkes DG: Pharmacology of exenatide (synthetic
exendin-4): a potential therapeutic for improved glycemic control of
type 2 diabetes. Regul Pept 2004, 117(2):77-88.
15. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD: Effects of
exenatide (exendin-4) on glycemic control and weight over 30 weeks in
metformin-treated patients with type 2 diabetes. Diabetes Care 2005,
28(5):1092-1100.
16. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS,
Baron AD: Effects of exenatide (exendin-4) on glycemic control over 30
weeks in patients with type 2 diabetes treated with metformin and a
sulfonylurea. Diabetes Care 2005, 28(5):1083-1091.
17. Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of
glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-
cell function in type 2 diabetes: a parallel-group study. Lancet 2002,
359(9309):824-830.
18. Zinman B, Hoogwerf BJ, Durán García S, Milton DR, Giaconia JM, Kim DD,
Trautmann ME, Brodows RG: The effect of adding exenatide to a
thiazolidinedione in suboptimally controlled type 2 diabetes: a
randomized trial. Ann Intern Med 2007, 146(7):477-485.
19. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH,
Wintle ME, Maggs DG: Exenatide effects on diabetes, obesity,
cardiovascular risk factors and hepatic biomarkers in patients with type
2 diabetes treated for at least 3 years. Curr Med Res Opin 2008,
24(1):275-286.
20. Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH,
Maggs DG, Wintle ME: Metabolic effects of two years of exenatide
treatment on diabetes, obesity, and hepatic biomarkers in patients with
Taylor et al. BMC Endocrine Disorders 2011, 11:9
http://www.biomedcentral.com/1472-6823/11/9
Page 8 of 9type 2 diabetes: an interim analysis of data from the open-label,
uncontrolled extension of three double-blind, placebo-controlled trials.
Clin Ther 2007, 29(1):139-153.
21. Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M,
Taylor K: Effects of once-weekly dosing of a long-acting release
formulation of exenatide on glucose control and body weight in
subjects with type 2 diabetes. Diabetes Care 2007, 30(6):1487-1493.
22. Tracy MA, Ward KL, Firouzabadian L, Wang Y, Dong N, Qian R, Zhang Y:
Factors affecting the degradation rate of poly(lactide-co-glycolide)
microspheres in vivo and in vitro. Biomaterials 1999, 20(11):1057-1062.
23. Ceriello A: Postprandial hyperglycemia and diabetes complications: is it
time to treat? Diabetes 2005, 54(1):1-7.
24. Monnier L, Lapinski H, Colette C: Contributions of fasting and
postprandial plasma glucose increments to the overall diurnal
hyperglycemia of type 2 diabetic patients: variations with increasing
levels of HbA(1c). Diabetes Care 2003, 26(3):881-885.
25. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D,
Porter L, DURATION-1 Study Group: Exenatide once weekly versus twice
daily for the treatment of type 2 diabetes: a randomised, open-label,
non-inferiority study. Lancet 2008, 372(9645):1240-1250.
26. Buse JB, Drucker DJ, Taylor KL, Kim T, Walsh B, Hu H, Wilhelm K,
Trautmann M, Shen LZ, Porter LE, DURATION-1 Study Group: DURATION-1:
exenatide once weekly produces sustained glycemic control and weight
loss over 52 weeks. Diabetes Care 2010, 33(6):1255-1261.
27. World Medical Association declaration of Helsinki: Recommendations
guiding physicians in biomedical research involving human subjects.
JAMA 1997, 277(11):925-926.
28. Gao Y, Yoon KH, Chuang LM, Mohan V, Ning G, Shah S, Jang HC, Wu TJ,
Johns D, Northrup J, et al: Efficacy and safety of exenatide in patients of
Asian descent with type 2 diabetes inadequately controlled with
metformin or metformin and a sulphonylurea. Diabetes Res Clin Pract
2009, 83(1):69-76.
29. Bantle JP, Wylie-Rosett J, Albright AL, Apovian CM, Clark NG, Franz MJ,
Hoogwerf BJ, Lichtenstein AH, Mayer-Davis E, Mooradian AD, et al:
Nutrition recommendations and interventions for diabetes–2006: a
position statement of the American Diabetes Association. Diabetes Care
2006, 29(9):2140-2157.
30. American Diabetes Association: Management of dyslipidemia in adults
with diabetes. Diabetes Care 2000, 23(Suppl 1):S57-S60.
31. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH,
Zychma M, Blonde L: Liraglutide once a day versus exenatide twice a day
for type 2 diabetes: a 26-week randomised, parallel-group, multinational,
open-label trial (LEAD-6). Lancet 2009, 374(9683):39-47.
32. Agersø H, Jensen LB, Elbrønd B, Rolan P, Zdravkovic M: The
pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211,
a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002,
45(2):195-202.
33. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-
Herman DE: Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as
monotherapy on glycemic control in patients with type 2 diabetes.
Diabetes Care 2006, 29(12):2632-2637.
34. Bergenstal R, Wysham C, MacConell L, Malloy J, Walsh B, Yan P, Wilhelm K,
Malone J, Porter L: Efficacy and safety of exenatide once weekly versus
sitagliptin or pioglitazone as an adjunct to metformin for treatment of
type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010,
376(9739):431-439.
35. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH,
MacConell L: Effects of exenatide versus sitagliptin on postprandial
glucose, insulin and glucagon secretion, gastric emptying, and caloric
intake: a randomized, cross-over study. Curr Med Res Opin 2008,
24(10):2943-2952.
36. Best JH, Boye KS, Rubin RR, Cao D, Kim TH, Peyrot M: Improved treatment
satisfaction and weight-related quality of life with exenatide once
weekly or twice daily. Diabet Med 2009, 26(7):722-728.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1472-6823/11/9/prepub
doi:10.1186/1472-6823-11-9
Cite this article as: Taylor et al.: Exenatide once weekly treatment
maintained improvements in glycemic control and weight loss over 2
years. BMC Endocrine Disorders 2011 11:9.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Taylor et al. BMC Endocrine Disorders 2011, 11:9
http://www.biomedcentral.com/1472-6823/11/9
Page 9 of 9